Last updated: June 8, 2026
Roxicet (oxycodone hydrochloride and immediate-release promethazine hydrochloride oral solution) is an older, short-acting opioid combination with ongoing clinical and label-lifecycle activity focused on safety, opioid risk management, and formulation/label stability. Market outlook in the US is constrained by opioid prescribing restrictions, generic availability dynamics for combination products, and competitive pressure from single-entity oxycodone generics, alternative opioid-antihistamine combinations, and non-opioid analgesics.
What is ROXICET (oxycodone + promethazine) and where is it used clinically?
ROXICET is an immediate-release opioid-antihistamine combination: oxycodone hydrochloride plus promethazine hydrochloride in an oral solution. The clinical positioning is acute pain requiring opioid analgesia, with promethazine used for its antihistamine and antiemetic properties, which also overlaps with sedation-related use in pain settings.
What does the ROXICET label typically cover (US)
Core label themes for this class and product include:
- Indication for management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
- Safety and warnings aligned with US opioid class labeling: risk of abuse, misuse, addiction; respiratory depression; neonatal opioid withdrawal syndrome; and life-threatening CNS depression risks.
- Promethazine class risks: sedation, anticholinergic effects, hypotension, and contraindications that frequently appear in the antihistamine labeling profile.
(Operational relevance: label content and boxed warnings influence payer coverage and prescribing controls, which directly drive market demand.)
What clinical trials exist for ROXICET, and what is the latest update?
No single ROXICET drug-development program dominates the clinical-trials record compared with modern opioid reformulations (extended-release oxycodone, abuse-deterrent technologies, or non-opioid analgesic pipelines). ROXICET’s clinical activity is more consistent with:
- Postmarketing safety reporting
- Labeling lifecycle updates (including REMS-adjacent opioid stewardship requirements)
- Bioequivalence or formulation work tied to generics and product lifecycle management rather than new efficacy endpoints
Trial pattern for older opioid-combination products
For older fixed-dose opioid combination products, the visible “clinical trials update” tends to come from:
- FDA regulatory milestones (CMC supplements, stability, formulation changes)
- Generic ANDA bioequivalence studies or bridging work
- Observational safety studies at the class level that reference opioid and opioid-antihistamine exposures
Clinical update that drives near-term access
The practical clinical update for ROXICET is less “new efficacy data” and more risk-management and prescribing environment changes. US opioid stewardship policies and prescriber controls reduce volume growth potential, even when product remains on-label.
What is the Orange Book status of ROXICET, and how many patents cover it?
ROXICET is treated by the market like a legacy combination product with an Orange Book footprint dominated by composition-of-matter, formulation, and/or method-related patents from earlier product generations. In practice, the patent estate for older oxycodone immediate-release products generally has long expired, with remaining value tied to:
- Specific formulation or manufacturing-process patents (if any still listed)
- Listed patents on particular strengths, dosage forms, or manufacturing steps
- Exclusivity protections only if they align with any later approvals
How to interpret Orange Book coverage for ROXICET
For legacy combination products, analysts typically face a pattern where:
- Multiple listed patents appear across years for different strengths or manufacturing methods
- Actual enforceability declines as composition and primary formulation patents expire
- The practical barrier for generics is more about manufacturing compliance and risk-based FDA review than patent life
(Note: a precise patent count, Orange Book listing numbers, and expiration dates require direct Orange Book listing extraction by NDC strength and manufacturer, which is not provided in the input.)
When does ROXICET lose exclusivity, and what are the likely generic entry risks?
For an older opioid combination product, the typical exclusivity reality is:
- Composition-of-matter and core formulation exclusivity is mostly expired
- Any remaining exclusivity is often limited to specific filings, manufacturing changes, or line extensions
Generic entry risk model for ROXICET
Generic entry risk is usually driven by:
- Whether an ANDA exists or is already approved for the same dosage form and strengths
- Whether any listed patents still have remaining life
- Whether the holder receives 30-month stays after Paragraph IV certifications
Because ROXICET is an older solution product and the combination is widely replicated historically, the market expectation is high generic substitutability, which limits pricing power.
Which companies are the main ROXICET competitors, and how does the competitive landscape look?
ROXICET competes primarily against:
- Single-entity immediate-release oxycodone generics (lower risk of supply restrictions and easier prescribing)
- Other oxycodone combination products with antihistamine/antiemetic agents (where available)
- Non-opioid analgesics and opioid-sparing regimens (NSAIDs, acetaminophen combinations, adjuvants)
- Other opioid classes (hydrocodone combos, tramadol where appropriate, and controlled-release products)
Market driver: prescriber preference and formulary behavior
Even if ROXICET remains available, formularies tend to favor:
- Lower-cost generics
- Simplified regimens that reduce adverse-event risk and drug interaction complexity
- Products with fewer “sedation” complications for patients with comorbidities
What patent litigation affects ROXICET, including Paragraph IV challenges and settlements?
For older combination products, the most visible litigation tends to cluster around:
- Paragraph IV ANDA filings for listed patents
- Settlements that shift launch dates or carve out specific strengths
A litigation-status update for ROXICET requires a docket-level review of the specific patents listed in the Orange Book, tied to the relevant ANDA filers and holders. That data is not included in the prompt, so it cannot be stated accurately.
How does ROXICET compare with alternative oxycodone combinations on patent and market strength?
Competitive parity is generally about substitutability, not patent durability. With legacy opioid combinations, the business reality is:
- Most efficacy differentiation is limited because immediate-release oxycodone provides the analgesic effect and promethazine provides symptomatic relief.
- Differences shift to dosing convenience, tolerability profiles, and supply continuity.
- Pricing pressure accelerates when multiple ANDAs exist.
Where ROXICET can still hold share is usually:
- Where it has entrenched formulary positioning in certain plans or hospital formularies
- Where clinicians historically use it for specific acute pain protocols
- Where supply disruptions in certain generic equivalents push uptake toward whichever product is reliably stocked
How big is the US market for ROXICET and what is the projection horizon?
ROXICET’s addressable market is an opioid-acuity segment shaped by acute pain prescribing. The projection is driven by three constraints:
- US opioid prescribing declines and tighter stewardship
- High generic substitutability that compresses net pricing
- Safety and adverse event scrutiny tied to opioid-antihistamine combinations
Business-grade projection framework (what to model)
Because ROXICET is a legacy product, analysts typically model:
- Volume: driven by acute pain prescriptions and substitution away from opioids
- Net price: driven by generic competition intensity
- Mix: influenced by plan formularies and prescriber protocols
- Supply: influenced by manufacturing and regulatory inspection risks
Projected direction (qualitative, market-analyst view)
- Base case: flat-to-declining US volume with continued price compression from generics.
- Bear case: further formulary erosion as plans tighten opioid preference tiers and opioid-antihistamine restrictions.
- Bull case: localized stability if ROXICET remains a preferred option in a subset of acute-care settings.
A numeric US dollar and unit projection requires third-party market volume data (IQVIA, Symphony Health, or similar), which is not part of the supplied input.
What regulatory issues influence ROXICET sales and label risk?
Regulatory risk for ROXICET is driven by opioid class requirements and FDA enforcement posture:
- Opioid boxed warning compliance and updated labeling
- Risk Evaluation and Mitigation Strategy expectations for opioid products across the class
- State-level opioid prescribing limits and PMP enforcement
- Additional scrutiny for sedating combinations due to CNS depression risk
How FDA actions usually translate into commercial impact
- Label updates can change contraindications and dosing guidance
- Safety communications can reduce prescriber willingness in certain populations
- REMS and stewardship programs can steer patients toward lower-risk regimens
What formulations are protected by patents for ROXICET, and what manufacturing/IP barriers exist?
For opioid solutions like ROXICET, formulation IP usually focuses on:
- Active ingredient ratios and stability-driven constraints
- Solvent systems and excipient composition
- Manufacturing method steps that control impurity profiles and dissolution/stability
IP barriers in legacy products are often modest compared with modern drug patents because core compound and broad formulation claims typically expire earlier. The remaining barriers, if any, are generally narrow and product-specific (strength/dosage form/manufacturing method).
Key Takeaways
- ROXICET is a legacy immediate-release opioid-antihistamine combination, with market prospects primarily constrained by opioid stewardship and generic substitutability.
- The “clinical trials update” is more consistent with postmarketing safety and lifecycle activity than major late-stage efficacy innovation.
- Exclusivity and patent leverage are likely limited given the age of the product class, but exact Orange Book counts, remaining patent terms, and litigation status require listing- and docket-level data.
- Near-term commercial outcomes depend mainly on formulary behavior, prescriber opioid policies, and generic competition intensity, not on new clinical efficacy breakthroughs.
FAQs
- Is ROXICET available as a generic, and how does generic substitution affect pricing?
- Does ROXICET have REMS or opioid class risk-management requirements that affect prescribing?
- What are the key safety risks of oxycodone plus promethazine versus oxycodone alone?
- How do state opioid prescribing rules and PDMP monitoring impact the acute pain market for ROXICET?
- What product strengths and NDCs drive ROXICET share in US acute-care formularies?
References
- FDA. (n.d.). Drug approvals and regulatory information for opioid-containing products (labeling, risk communications, and class requirements). FDA.
- US FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- FDA. (n.d.). Opioid safety communications, boxed warnings, and REMS-related information. FDA.
